SCHEMBL6093797

SCHEMBL6093797

COc1ccc(CNC[C@H](C)c2ccc(Cl)cc2)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.59
MEN1 O00255 6/20 0.59
NPSR1 Q6W5P4 4/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
RECQL P46063 1/20 0.56
PLK1 P53350 1/20 0.51
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
POLB P06746 1/20 0.48
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095457 0.86 MEN1 (0.60) KMT2AMEN1NPSR1ALDH1A1KDM4E
SCHEMBL6095459 0.86 MEN1 (0.60) KMT2AMEN1NPSR1ALDH1A1KDM4E
SCHEMBL6095014 0.86 KMT2A (0.62) KMT2AMEN1LMNAHTTALDH1A1
SCHEMBL6092685 0.86 KMT2A (0.62) KMT2AMEN1LMNAHTTALDH1A1
SCHEMBL6092690 0.86 KMT2A (0.62) KMT2AMEN1LMNAHTTALDH1A1
Hydrochloric Acid SCHEMBL11792825 0.84 LMNA (0.59) KMT2AMEN1NPSR1LMNAHTT
SCHEMBL6094413 0.78 L3MBTL1 (0.55) KMT2AMEN1LMNAHTTKDM4E
SCHEMBL6094415 0.78 L3MBTL1 (0.55) KMT2AMEN1LMNAHTTKDM4E
SCHEMBL6272264 0.78 L3MBTL1 (0.55) KMT2AMEN1LMNAHTTKDM4E
SCHEMBL23022855 0.78 BCHE (0.52) KMT2AMEN1LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078565-B2 Benzamide derivatives as antagonists of orexin receptors SMITHKLINE BEECHAM PLC (GB) 2006-07-18 US disclosed
EP-1440052-B1 BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2005-12-14 EP disclosed
US-20050020584-A1 Benzamide derivatives as antagonists of orexin receptors SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-27 US disclosed
EP-1440052-A1 BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2004-07-28 EP disclosed
WO-2003037847-A1 BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS SMITHKLINE BEECHAM P.L.C. (GB) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020584-A1 Benzamide derivatives as antagonists of orexin receptors HCRTR2, HCRTR1, OXTR KMT2A 793/4885MEN1 2183/4885NPSR1 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.